• Investors
  • News
  • Subscribe
Hit enter to search or ESC to close
Cardax, Inc. | CDXI
  • About Us
    • Corporate Overview
    • Corporate Presentation
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Lead Scientific Team
    • Company History
  • Astaxanthin
    • Overview
      • Astaxanthin Overview
      • History and Background
      • Safety
      • Mechanism of Action
      • Synthetic vs. Natural Astaxanthin
    • Research in Key Addressable Markets
      • Cardiovascular Disease
      • Metabolic Disease
      • Liver Disease
      • Arthritis
      • Aging
      • Coronavirus Disease 2019 (COVID-19)
    • Scientific Literature
  • Programs
    • Product Platform
    • Commercialization Strategy
    • CDX-101
    • CDX-301
    • ZanthoSyn®
    • CHASE Clinical Trial
    • Intellectual Property
  • Newsroom
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
Cardax, Inc. | CDXI

Press Releases

Investor Relations
Investors
  • Overview
  • News / Events
    • Press Releases
    • Media Coverage
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Profile
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

Cardax Astaxanthin Compound Chosen for Important NIH Anti-Aging Research Program

Jun 18, 2017

Cardax Q1 2017 Revenues Triple vs. Prior Two Quarters Combined

May 15, 2017

Cardax Astaxanthin Compound CDX-085 Stimulates Anti-Aging Gene in Mice

Mar 28, 2017

Cardax Secures Access to Funds Under Equity Purchase Agreement

Feb 9, 2017

Cardax Takes Important Step to Access Funds Under Equity Purchase Agreement

Feb 8, 2017

Cardax Announces Launch of ZanthoSyn™ in Hawaii GNC Stores

Jan 25, 2017

Cardax Appoints Global Healthcare Executive as Independent Director

Jan 10, 2017

Cardax Reports Successful Launch of ZanthoSyn™

Nov 14, 2016

Cardax Launches First Product ZanthoSyn™

Aug 24, 2016

Cardax Enters Into Equity Purchase Agreement for Financing of Up to $5 Million

Jul 18, 2016
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8

    News / Events

    • Press Releases
    • Media Coverage
    • IR Calendar
    • Presentations
    • Email Alerts
    Subscribe to Receive Updates by E-Mail Cardax News Alerts

    Recent News

    • Cardax Reports Q3 2020 ResultsNovember 13, 2020
    • Cardax Reports Q2 2020 ResultsAugust 14, 2020

    © 2021 Cardax, Inc. | Disclaimer and Terms of Use

    • About Us
      • Corporate Overview
      • Corporate Presentation
      • Management Team
      • Board of Directors
      • Scientific Advisory Board
      • Lead Scientific Team
      • Company History
    • Astaxanthin
      • Overview
        • Astaxanthin Overview
        • History and Background
        • Safety
        • Mechanism of Action
        • Synthetic vs. Natural Astaxanthin
      • Research in Key Addressable Markets
      • Scientific Literature
    • Programs
      • Product Platform
      • Commercialization Strategy
      • CDX-101
      • CDX-301
      • ZanthoSyn®
      • CHASE Clinical Trial
      • Intellectual Property
    • Newsroom
    • Investors
      • Investor Overview
      • News / Events
      • Company Information
      • Financial Information
      • Stock Information
      • SEC Filings
      • Corporate Governance
    • Contact Us
    • Investors
    • News
    • Subscribe